FSU Jena, Institute for Clinical Chemistry and Laboratory Diagnostics, Germany.
Platelets. 2010;21(5):314-9. doi: 10.3109/09537101003763442.
Whole blood aggregometry on the is a simple, fast and standardized method and it is widely used to assess platelet function under antiplatelet therapy. Reference ranges and a cut-off value as a measure of ASA response were established by measuring arachidonic acid induced aggregation (ASPI-test) in healthy volunteers and cardiac patients after and used to classify patients as ASA responders or non-responders. However, assessing the platelet function is highly affected by pre-analytical and analytical conditions and often reduced aggregation by TRAP induced aggregation (TRAP-test) is seen, rendering the samples difficult for interpretation of the ASPI-test and the responder status to ASA. We hypothesised that in this simplified model any preanalytical factor has the same effect on TRAP-testing as on ASPI-testing and that by calculating the ratio between a defined, normal TRAP-test result and the TRAP-test result measured for the individual patient this ratio could be applied to the measured ASPI-test thereby reaching a more valid discrimination between ASA responders and -non-responders. TRAP- and ASPI-test were performed in blood from ASA-treated volunteers and controls on Multiplate before an after pneumatic tube delivery as a model to stimulate shear stress induced platelet activation and aggregation. The calculated, normalised ASPI test result after tube delivery did not differ significantly from the initial ASPI test result although tube delivery had a significant impact on the measured ASPI test result. If applied to patients samples a definite judgement on the ASA response status of patients with reduced "general platelet activatability" could be given. Normalisation of the ASPI-test result using the TRAP-test result may provide a method to judge on the ASA response status in patients with decreased initial "general platelet activatability".
全血聚集测定是一种简单、快速和标准化的方法,广泛用于评估抗血小板治疗下的血小板功能。通过测量健康志愿者和心脏病患者在用阿司匹林治疗后诱导的花生四烯酸聚集(ASPI 试验),建立了参考范围和作为阿司匹林反应的截断值,并用于将患者分类为阿司匹林反应者或非反应者。然而,血小板功能的评估受到分析前和分析条件的高度影响,经常会出现由血栓素 A2 诱导的聚集(TRAP 试验)引起的聚集减少,从而使样本难以解释 ASPI 试验和阿司匹林的反应状态。我们假设在这个简化的模型中,任何分析前因素对 TRAP 试验的影响与对 ASPI 试验的影响相同,并且通过计算定义的正常 TRAP 试验结果与个体患者测量的 TRAP 试验结果之间的比值,可以将该比值应用于测量的 ASPI 试验,从而在阿司匹林反应者和非反应者之间实现更有效的区分。TRAP 试验和 ASPI 试验在接受阿司匹林治疗的志愿者和对照者的血液中在 Multiplate 上进行,在气动输送前后作为刺激剪切应力诱导的血小板激活和聚集的模型。尽管气动输送对测量的 ASPI 试验结果有显著影响,但输送后的计算归一化 ASPI 试验结果与初始 ASPI 试验结果无显著差异。如果应用于患者样本,可以对血小板活性降低的患者的阿司匹林反应状态做出明确的判断。使用 TRAP 试验结果对 ASPI 试验结果进行归一化可能提供一种方法来判断初始“一般血小板活性”降低的患者的阿司匹林反应状态。